94193-36-9

Usage

Uses

Used in Chemical Synthesis:
4-(3-FORMYL-4-NITRO-PHENOXY)-BUTYRIC ACID is used as an intermediate in the synthesis of other organic compounds for various applications, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique functional groups allow for versatile reactions and the formation of diverse chemical products.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 4-(3-FORMYL-4-NITRO-PHENOXY)-BUTYRIC ACID is used as a building block for the development of new drugs. Its chemical structure can be modified to create molecules with specific therapeutic properties, making it a valuable asset in drug discovery and design.
Used in Research and Development:
4-(3-FORMYL-4-NITRO-PHENOXY)-BUTYRIC ACID is utilized in research and development settings to study the effects of its functional groups on chemical reactions and properties. This knowledge can be applied to the design of new materials, catalysts, and other chemical products with tailored characteristics.
Used in Industrial Processes:
In industrial applications, 4-(3-FORMYL-4-NITRO-PHENOXY)-BUTYRIC ACID can be employed as a reactant or catalyst in various chemical processes. Its presence can enhance the efficiency of reactions, improve product yields, or enable the production of materials with specific properties.

InChI:InChI=1/C11H11NO6/c13-7-8-6-9(3-4-10(8)12(16)17)18-5-1-2-11(14)15/h3-4,6-7H,1-2,5H2,(H,14,15)

Upstream product

• 94193-35-8 ethyl 4-((3-formyl-4-nitrophenyl)oxy)butyrate 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 100-83-4 meta-hydroxybenzaldehyde 
• 99306-51-1 bis(3-formylphenyl) oxalate 

Downstream Products

• 105763-67-5 {5-[3-(Cyclohexyl-methyl-carbamoyl)-propoxy]-2-nitro-benzylamino}-acetic acid ethyl ester 
• 105695-33-8 N-Cyclohexyl-N-(4-hydroxy-butyl)-4-(2-oxo-1,2,3,5-tetrahydro-imidazo[2,1-b]quinazolin-7-yloxy)-butyramide 
• 105695-34-9 N-Cyclohexyl-N-(5-hydroxy-pentyl)-4-(2-oxo-1,2,3,5-tetrahydro-imidazo[2,1-b]quinazolin-7-yloxy)-butyramide 
• 105695-35-0 N-cyclohexyl-N-(6-hydroxyhexyl)-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramide 
• 105763-55-1 {2-Amino-5-[3-(cyclohexyl-methyl-carbamoyl)-propoxy]-benzyl}-carbamic acid phenyl ester 
• 105695-36-1 N-Cyclohexyl-N-(2-hydroxy-1-hydroxymethyl-ethyl)-4-(2-oxo-1,2,3,5-tetrahydro-imidazo[2,1-b]quinazolin-7-yloxy)-butyramide 
• 94192-67-3 N,N-dicyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramide 

Relevant academic research and scientific papers

Nifursol hapten, artificial antigen, and preparation method and application thereof

The invention relates to the field of biochemical engineering, and specifically relates to a nifursol hapten, an artificial antigen, and a preparation method and application thereof. The structure of the nifursol hapten is shown as a formula (I), the artificial antigen is obtained after the nifursol hapten is coupled with carrier protein, the artificial antigen is used as an immunogen to prepare a corresponding hybridoma cell 3H10, and a monoclonal antibody secreted by the hybridoma cell 3H10 can be used for detecting nifursol. A monoclonal antibody prepared by immunizing a mouse with an artificial antigen prepared from the nifursol hapten provided by the invention has relatively high sensitivity in detection of nifursol and derivatives thereof, and a new material basis is provided for establishing a rapid, simple, cheap, sensitive and specific nifursol detection method.

Hapten synthesis, monoclonal antibody production and immunoassay development for direct detection of 4-hydroxybenzehydrazide in chicken, the metabolite of nifuroxazide

Derivatization is usually employed in immunoassay for detection of metabolites of nitrofurans and avoiding derivatization could be preferable to achieve an efficient screening. In the study, we designed four haptens of 4-hydroxybenhydrazide (HBH), the nifuroxazide metabolite. The effect of hapten structures on antibody affinity were evaluated and one monoclonal antibody was produced by using the Hapten C with a linear alkalane spacer arm. After optimization, an enzyme linked-immunosorbent assay (ELISA) was established with an 50% inhibition concentration of 0.25 ng mL?1 for HBH, which could ensure the direct detection of HBH without derivatization. The limit of detection of the ELISA for HBH was 0.12 μg kg?1 with the recoveries of 90.1–96.2% and coefficient of variation (CV) values lower than 9.1%. In conclusion, we produced several high affinity antibodies to HBH with new designed hapten and developed an icELISA for the direct detection of HBH without derivatization in chicken.

Nifuraldezone hapten and artificial antigen as well as preparation method and application thereof

The invention relates to nifuraldezone hapten and artificial antigen as well as a preparation method and application thereof. The nifuraldezone hapten has a structural formula (I) or (II) shown in thedescription. The nifuraldezone artificial antigen is prepared by coupling the hapten of the formula (I) or (II) with a carrier protein. When the nifuraldezone artificial antigen is adopted to immunize animals, specific antibodies with high valences and high sensitivity can be obtained. By adopting the nifuraldezone hapten and antibodies prepared from same, novel means for establishing rapid, simple, cheap, sensitive and specific nifuraldezone detection methods can be provided.

Preparation method and application of derived hapten and artificial antigen of furazolidone metabolite AOZ

The invention discloses a preparation method and application of a derived hapten and an artificial antigen of a furazolidone metabolite AOZ. An active arm introduced into the hapten completely retains a feature structure of an AOZ derivative and has no in

Preparation methods and application of semicarbazide SEM derived hapten and artificial antigen

The invention discloses preparation methods and application of semicarbazide SEM derived hapten and artificial antigen. An active arm introduced by the hapten integrally keeps a characteristic structure of an SEM derivative and has no influences on electr

Macrodantin metabolite AHD derivatization semiantigen, and preparation method and application of artificial antigen

The invention discloses a macrodantin metabolite AHD derivatization semiantigen, and a preparation method and application of an artificial antigen. An active arm introduced by the semiantigen completely retains a characteristic structure of an AHD derivat

Photodegradable macromers and hydrogels for live cell encapsulation and release

Hydrogel scaffolds are commonly used as 3D carriers for cells because their properties can be tailored to match natural extracellular matrix. Hydrogels may be used in tissue engineering and regenerative medicine to deliver therapeutic cells to injured or diseased tissue through controlled degradation. Hydrolysis and enzymolysis are the two most common mechanisms employed for hydrogel degradation, but neither allows sequential or staged release of cells. In contrast, photodegradation allows external real-time spatial and temporal control over hydrogel degradation, and allows for staged and sequential release of cells. We synthesized and characterized a series of macromers incorporating photodegradbale ortho-nitrobenzyl (o-NB) groups in the macromer backbone. We formed hydrogels from these macromers via redox polymerization and quantified the apparent rate constants of degradation (kapp) of each via photorheology at 370 nm, 10 mW/cm2. Decreasing the number of aryl ethers on the o-NB group increases kapp, and changing the functionality from primary to seconday at the benzylic site dramatically increases kapp. Human mesenchymal stem cells (hMSCs) survive encapsulation in the hydrogels (90% viability postencapsulation). By exploiting the differences in reactivity of two different o-NB linkers, we quantitatively demonstrate the biased release of one stem cell population (green-fluoroescent protein expressing hMSCs) over another (red-fluorescent protein expressing hMSCs).

1H-1,2,4-thiadiazolo(3,4-b)quinazolin-5-one-2,2-dioxides, and a method for increasing the cardiac output of a mammal with them

1H-1,2,4-thiadiazolo[3,4-b]quinazolin-5-one-2,2-dioxides are disclosed. These compounds are useful as caridotonic agents. A preferred compound is 7-(n-cyclohexyl-N-methyl-4-amino-4-oxobutyloxy)-1H-1,2,4-thiadiazolo[3,4-b]quinazolin-5-one-2,2-dioxide.

(2-Oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl) oxyalkylamides properties having phosphodiosterase inhibiting

Compounds according to the formula STR1 , its optical isomers, or a pharmaceutically acceptable salt thereof wherein: m and n are integers of 1 to 6; R1 is hydrogen or alkyl of 1 to 4 carbons; R2 is hydrogen or R1 and R2 are combined to form an oxo group; R3 is hydrogen, alkyl of 1 to 6 carbons, phenyl, benzyl, hydroxy lower alkyl and its aliphatic acylates of 1 to 6 carbon atoms or aryl acylates of 7 to 12 carbon atoms, carbamoyl alkyl, carboxyalkyl, alkoxycarbonylalkyl or α-amino acid side chains; R4 is hydrogen, alkyl of 1 to 6 carbons, benzyl, or hydroxy lower alkyl; R5 is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring is unsubstituted or substituted with a lower alkyl, lower alkoxy, --OH, --OCOR6, halo, --NH2, --N(R6)2, --NHCOR6, --COOH, or --COO(R6) group wherein R6 is lower alkyl; phenyl or phenyl lower alkyl wherein phenyl is unsubstituted or substituted with 1 or more lower alkyl, halo or lower alkoxy groups or an --NH2, --N(R6)2, --NHCOR6, --COOH, or --COOR6 group wherein R6 is lower alkyl; Y is hydrogen, alkyl of 1 to 4 carbon atoms, halo or lower alkoxy; and Z is --OR7 or --NR7 R8 wherein R7 and R8 are independently hydrogen or lower alkyl.

(2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors

This invention relates to compounds of the formula (I) and the pharmaceutically acceptable acid addition salts thereof wherein the various substituents are defined herein. These compounds are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agents in mammals